Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.
Developing non-opioid analgesics remains one of the hardest tasks in biopharma.
A clinical hold for Pharvaris raises questions about the group’s approach, and could leave the door open for its acute rival.
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.
Venture capital has the brains, private equity has the books – can they make lots of money?
Seagen is vulnerable to takeover, but whether a deal happens – and at what price – depends on at least one catalyst.
After Idorsia’s tease in resistant hypertension, data will soon emerge on other advanced assets, including long-acting RNA-based approaches.
New devices are coming, but the real advances will involve combinations.